

## **PRESS RELEASE**

Morepen Laboratories Limited, having USFDA approved facilities in Himachal Pradesh for manufacturing LORATADINE & DESLORATADINE has registered recorded Sales revenues of Rs. 296 Crores during the current financial ending March 2013. The company has posted a growth of 13% over the last year revenues of Rs. 261 Crores.

API business of the company during the year was at Rs. 191 Crores, recording a growth of 13% over the last year. The major contribution is coming from API Business .

Under its API business the company has doubled the capacity of its anti-asthmatic drug Montelukast Sodium to 24MT/annum and recorded the highest topline of Rs. 54.5 Crores in F.Y. 2012-13. Morepen is the largest manufacturer of Montelukast in India & it is expected to show a very good growth in the coming years. The company has also got registered this product in China, Korea & Thailand.

Its formulation, diagnostics and contract manufacturing business at Rs. 105 Crores have also recorded impressive growth of 17% in their sales revenues. Morepen has established its "Home Health" brand in the home diagnostics field in the domestic market & has taken its position as leading domestic brand in the category of Blood Pressure Monitors, Glucometers , Digital Thermometers & Weighing Scales.

OTC business carried out under 100% owned subsidiary "Dr. Morepen" has recorded sales revenue of Rs. 25.8 Crores, a growth of 11% over last year. While Dr. Morepen 'Burnol' remains the leading product in the Burn category , Lemolate is getting a good hold in the Cold & Fever market .

The Company has gained domestic market share by 22 % while exports have grown by 6% . Current Year EBIDTA at Rs. 31.6 Crores have shown a growth of more than 69% over last year EBIDTA of Rs. 18.7 Crores. Cash profits at Rs. 20 Crores have gone up by 87% over last year of Rs. 10.7 Crores. The company is back on the growth track & targeting to the launch some of the new molecules in the field of anti-diabetic & anti-hypertensive category.